Compare Honeywell International Inc (HON) vs Tempus AI (TEM) Price & Performance

Honeywell International (HON) trades at $225.78, up 0.34% with a bullish technical signal and strong institutional support. The company maintains solid fundamentals with a 10.89% net margin and 26.41% ROE, though recent earnings show mixed trends with Q1 2026 beating expectations but full-year 2026 guidance indicating potential decline. Recent developments include the completion of a £1.325 billion acquisition and a 2:1 reverse stock split.

The outlook remains positive with analyst consensus favoring Buy ratings (65.52%) and a $368.55 price target representing significant upside. Key risks include execution challenges post-spinoffs and margin pressure, while opportunities lie in automation growth and strategic acquisitions. The stock presents a balanced risk-reward profile for long-term investors.

Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.

The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.